Oncology and hematology

腫瘍・血液内科について

最新年度業績

2026年

  1. Yamamoto K, Kurata K, Yakushijin K, Minami H. Complex t(8;14;18)(q24;q32;q21) Together With Novel t(3;6)(q27;p23) in Triple-Hit High-Grade B-Cell Lymphoma Showing Burkitt-Like Cytology.Int J Lab Hematol. 2026 Feb;48(1):5-8. doi: 10.1111/ijlh.70018. Epub 2025 Oct 23.


    https://pubmed.ncbi.nlm.nih.gov/41131724/

  2. Masuda S, Imamura Y, Shimoyama R, Uryu K, Mase T, Taguri M, Okuda T, Shiragami M, Fujimura Y, Hayashi M, Minami H. Optimizing chemotherapy regimens and dosing for older patients with metastatic pancreatic cancer: insights from the Tokushukai real-world data project. BMC Cancer. 2026 Feb 13;26(1):378. doi: 10.1186/s12885-026-15711-1.


    https://pubmed.ncbi.nlm.nih.gov/41688942/

  3. Inase A, Kimbara S, Imamura E, Phelps M, Minami H. Overcoming resistance to antibody-drug conjugates: mechanisms and emerging strategies.Oncologist. 2026 Mar 9;31(4):oyag020. doi: 10.1093/oncolo/oyag020.


    https://pubmed.ncbi.nlm.nih.gov/41630503/

  4. Singer S, Amdal CD, Bjordal K, Herlofson BB, Astrup GL, Boehm A, Wöhner U, Hammerlid E, Gama RR, Jacinto AA, Jansen F, Verdonck-de Leeuw IM, Dragan T, Duprez F, Kiyota N, Pinto M, Krüger M, Guntinas-Lichius O, Inhestern J, Tramacere F, Bonomo P, Fanetti G, Nuyts S, Plath M, Stempler N, Westgaard KL, Taylor KJ. Late Toxicity and Long-Term Quality of Life in Survivors of Cancer of the Major Salivary Glands More Than 5 Years After Diagnosis: A Multi-National Study.Head Neck. 2026 Jan;48(1):13-25. doi: 10.1002/hed.28263. Epub 2025 Aug 1.


    https://pubmed.ncbi.nlm.nih.gov/40747834/

  5. Kimura SI, Kawamura S, Toya T, Okinaka K, Hosoi H, Uchida N, Doki N, Nishida T, Tanaka M, Hasegawa Y, Kanda Y, Asada N, Kurita N, Nakamae H, Eto T, Yoshimitsu M, Onizuka M, Fukuda T, Ohbiki M, Atsuta Y, Yakushijin K. Letermovir prophylaxis and risk of bacterial or fungal infection after allogeneic hematopoietic cell transplantation.J Infect Chemother. 2026 Jan;32(1):102888. doi: 10.1016/j.jiac.2025.102888. Epub 2025 Dec 8.


    https://pubmed.ncbi.nlm.nih.gov/41371495/

  6. Kimikazu Yakushijin1, Jacinta Perram2, Aloysius Ho3, Tasneem Farzana4, Hiroatsu Iida5, Jong Wook Lee6, Yoshihiro Inamoto7, Biju George8, Depei Wu9, Ritsuro Suzuki10, Maryam Behfar11,12, He Huang13, Thiti Asawapanumas14, Philip Rowlings15, Bishesh S. Poudyal16, Damai Santosa17, Aye Aye Gyi18, Otgonbat Altangerel19, Chinadol Wanitpongpun20, Gin Gin Gan21, Satoshi Iyama22, Shahid Iqbal23, Mani Ramzi24, Alka Khadwal25, Jun Kato26, Joycelyn Sim27, Jessica Cheng2, David Ma2, Yi Xuan Chua28, Shinichiro Okamoto26, Minako Iida29, Shigeo Fuji30 International Survey for Antiemetics in Hematopoietic Stem Cell Transplantation in the APBMT Centers.Blood Cell Ther. 2026 Jan 9;9(1):9-16. doi: 10.31547/bct-2025-020. eCollection 2026 Feb 25.


    https://pubmed.ncbi.nlm.nih.gov/41815184/

  7. Yanagisawa R, Miyamoto S, Sasahara Y, Kajiwara M, Ishimura M, Sakaguchi H, Doi T, Takahashi Y, Cho Y, Sato M, Katayama S, Koh K, Yanagimachi M, Hasegawa D, Okada K, Takita J, Saito S, Sato A, Hino M, Matsumoto K, Tabuchi K, Yakushijin K, Umeda K. Effect of Inflammatory Bowel Disease on Clinical Outcomes of Hematopoietic Cell Transplantation for Inborn Errors of Immunity.Transplant Cell Ther. 2026 Feb;32(2):203.e1-203.e11. doi: 10.1016/j.jtct.2025.11.006. Epub 2025 Nov 10.


    https://pubmed.ncbi.nlm.nih.gov/41224146/

  8. Hiroaki Nagashima,Yasuhide Takeuchi,Naoe Jimbo,Hadzki Matsuda,Shiro Kinbara,Kazuhiro Tanaka,Takashi Sasayama CUX1::MET fusion defines an indolent subtype of diffuse low-grade glioma, MAPK pathway-altered.Acta Neuropathol Commun. 2026 Mar 3. doi: 10.1186/s40478-026-02271-5. Online ahead of print.


    https://pubmed.ncbi.nlm.nih.gov/41776606/

2025年

  1. Taira N, Kiyota N, Kikawa Y, Ichihara E, Kato K, Kubota K, Tateishi R, Nakata A, Nakamura K, Narita Y, Hotta K Iwata H, Gemma A, Shimozuma K, Muro K, Iwamoto T, Takumoto T, Shiroiwa T, Fukuda T, Yamaguchi T, Hagiwara Y, Minami H. Multicenter, open-label, randomized, controlled study to test the utility of electronic patient-reported outcome monitoring in patients with unresectable advanced cancers or metastatic/recurrent solid tumors.Jpn J Clin Oncol. 2025 Apr 26;55(5):547-555. doi: 10.1093/jjco/hyaf033.


    https://pubmed.ncbi.nlm.nih.gov/39987488/

  2. Hochhaus A, Kim D-W, Cortes JE, Sasaki K, Mauro MJ, Hughes TP, Breccia M, Talpaz M, Minami H, Goh YT, DeAngelo DJ, Lang F, Ottmann O, Heinrich M, Gomez Garcia de Soria V, le Coutre P, Sanchez-Olle G, Cao M, Pognan N, Kapoor S, Hoch M, Rea D. Asciminib monotherapy in patients with chronic myeloid leukemia in chronic phase without BCR::ABL1T315I treated with at least 2 prior TKIs: Phase 1 final results.Leukemia. 2025 May;39(5):1114-1123. doi: 10.1038/s41375-025-02578-7. Epub 2025 Apr 9.


    https://pubmed.ncbi.nlm.nih.gov/40204892/

  3. Cortes JE, Lang F, Rea D, Hochhaus A, Breccia M, Goh YT, Heinrich MC, Hughes TP, Janssen JJWM, le Coutre P, Minami H, Sasaki K, DeAngelo DJ, Olle GS, Pognan N, Cao M, Hoch M, Mauro MJ. Asciminib in combination with imatinib, nilotinib, or dasatinib in patients with chronic myeloid leukemia in chronic or accelerated phase: phase 1 study final results.Leukemia. 2025 May;39(5):1124-1134. doi: 10.1038/s41375-025-02592-9. Epub 2025 Apr 9


    https://pubmed.ncbi.nlm.nih.gov/40204896/

  4. Uryu K, Imamura Y, Shimoyama R, Mase T, Fujimura Y, Hayashi M, Ohtaki M, Otani K, Hibino M, Horiuchi Shigeto, Fukui T, Fukai R, Chihara Y, Iwase A, Yamada N, Tamura Y, Harada H, Tsuya A, Okabe T, Fukuoka M, Minami H. Public assistance and survival equality in patients with EGFR mutation-positive lung cancer.Jpn J Clin Oncol. 2025 Mar 5;55(3):228-236. doi: 10.1093/jjco/hyae167.


    https://pubmed.ncbi.nlm.nih.gov/39673402/

  5. Yamamoto K, Kurata K, Yakushijin K, Minami H. Ring Chromosomes 7 in Two Cases of Myelodysplastic Syndrome: Isolated Abnormality and Complex Karyotype Including idic(21)(p11.2) Duplication.Int J Lab Hematol. 2025 Oct;47(5):791-793. doi: 10.1111/ijlh.14499.


    https://pubmed.ncbi.nlm.nih.gov/40387243/

  6. Okazoe-Hirakawa Y, Yakushijin K, Kurata K, Matsumoto S, Ichikawa H, Sakai R, Nose T1, Kimbara S, Nagatani Y, Koyama T, Inui Y, Funakoshi Y, Kiyota N, Ito M, Hatazawa K, Tanaka H, Yamamoto N, Minami H. Importance of E/e' and BNP for early detection of late cardiotoxicity in long-term follow-up of childhood hematologic cancer survivors: a retrospective cross-sectional study9.Cardiooncology.2025 Jun 19;11(1):55. doi: 10.1186/s40959-025-00354-1.


    https://pubmed.ncbi.nlm.nih.gov/40537853/

  7. Fukui T, Imamura Y, Kakutani T, Uryu K, Shimoyama R, Okuda T, Kataoka K, Taguri M, Minami H. Real-world evidence on the survival benefit of immune checkpoint inhibitors in combination with cytotoxic chemotherapy for patients with extensive-disease small-cell lung cancer: the Tokushukai Real World Data Project (TREAD) 06.BMC Cancer. 2025 Aug 27;25(1):1379. doi: 10.1186/s12885-025-14701-z.


    https://pubmed.ncbi.nlm.nih.gov/40866909/

  8. Matsumoto S, Funakoshi Y, Yakushijin K, Matsutani T, Okazoe-Hirakawa Y, Ohji G, Koyama T, Nagatani Y, Kurata K, Kimbara S, Kiyota N, Minami H. Humoral immunity after hematopoietic stem cell transplantation: evaluation by B-cell receptor repertoire analysis.Int J Hematol. 2025 Dec;122(6):877-884. doi: 10.1007/s12185-025-04042-9. Epub 2025 Jul 25.


    https://pubmed.ncbi.nlm.nih.gov/40711664/

  9. Shimoyama R, Imamura Y, Uryu K, Mase T, Taguri M, Okuda T, Shiragami M, Fujimura Y, Hayashi M, Minami H. Negative Impact of Coronavirus Disease 2019 Pandemic on Gastric Cancer Care in Japan: A Tokushukai Real-World Data Project 08 (TREAD 08). JGH Open. 2025 Oct 3;9(10):e70285. doi: 10.1002/jgh3.70285. eCollection 2025 Oct.


    https://pubmed.ncbi.nlm.nih.gov/41048823/

  10. Hochhaus A, Kim D-W, Cortes JE, Sasaki K, Mauro MJ, Hughes TP, Breccia M, Talpaz M, Minami H, Goh YT, DeAngelo DJ, Lang F, Ottmann O, Heinrich M, Gomez Garcia de Soria V, le Coutre P, Sanchez-Olle G, Cao M, Pognan N, Kapoor S, Hoch M, Rea D. Asciminib monotherapy in patients with chronic myeloid leukemia in chronic phase without BCR::ABL1T315I treated with at least 2 prior TKIs: Phase 1 final results.Leukemia. 2025 May;39(5):1114-1123. doi: 10.1038/s41375-025-02578-7. Epub 2025 Apr 9.


    https://pubmed.ncbi.nlm.nih.gov/40204892/

  11. Shimoyama R, Imamura Y, Uryu K, Mase T, Taguri M, Okuda T, Shiragami M, Fujimura Y, Hayashi M, Minami H. Negative Impact of Coronavirus Disease 2019 Pandemic on Gastric Cancer Care in Japan: A Tokushukai Real-World Data Project 08 (TREAD 08).JGH Open. 2025 Oct 3;9(10):e70285. doi: 10.1002/jgh3.70285. eCollection 2025 Oct.


    https://pubmed.ncbi.nlm.nih.gov/41048823/

  12. Yoshiaki Nagatani , Naomi Kiyota , Tomoko Yamazaki , Yukinori Asada , Masaaki Higashino , Hironaga Satake , Shogen Boku , Ari Nishimura , Hirokazu Uemura , Ichiro Ota , Katsunari Yane , Kaoru Tanaka , Takuma Onoe , Yuji Hirayama , Takahiro Tsujikawa , Hajime Fujiwara , Hikari Shimoda , Ken-Ichi Nibu , Yoshinori Imamura , Shiro Kimbara , Taiji Koyama , Yohei Funakoshi , Hironobu Minami. A phase II trial of nivolumab for patients with platinum-refractory recurrent or metastatic salivary gland cancer.Jpn J Clin Oncol. 2026 Mar 13;56(3):274-281. doi: 10.1093/jjco/hyaf192.


    https://pubmed.ncbi.nlm.nih.gov/41342548/

  13. Mishima C, Yakushijin K, Fukuoka H, Takahashi R, Okazoe Y, Joyce M, Matsumoto S, Sakai R, Inui Y, Kurata K, Minami H. A Rare Case of Pseudohypercalcemia Associated with Multiple Myeloma.Kobe J Med Sci. 2025 May 30;71(2):E46-E49. doi: 10.24546/0100495981.


    https://pubmed.ncbi.nlm.nih.gov/40610015/

  14. Matsuda T, Nagatani Y, Funakoshi Y, Tsuboyama T, Mii Y, Kaneda K, Tanaka T, Hasegawa H, Yamashita K, Kiyota N, Minami H, Kakeji Y. Neoadjuvant FOLFOXIRI plus bevacizumab without radiotherapy for high-risk rectal cancer: multicentre phase II trial.BJS Open. 2025 Dec 29;10(1):zraf163. doi: 10.1093/bjsopen/zraf163.


    https://pubmed.ncbi.nlm.nih.gov/41661200/

  15. Fukui T, Imamura Y, Kakutani T, Uryu K, Shimoyama R, Okuda T, Kataoka K, Taguri M, Minami H. Real-world evidence on the survival benefit of immune checkpoint inhibitors in combination with cytotoxic chemotherapy for patients with extensive-disease small-cell lung cancer: the Tokushukai Real World Data Project (TREAD) 06.BMC Cancer. 2025 Aug 27;25(1):1379. doi: 10.1186/s12885-025-14701-z.


    https://pubmed.ncbi.nlm.nih.gov/40866909/

  16. Kiyota N, Koyama T, Sugitani I. Anticancer drug therapy for anaplastic thyroid cancer.Eur Thyroid J. 2025 Apr 14;14(2):e240287. doi: 10.1530/ETJ-24-0287. Print 2025 Apr 1.


    https://pubmed.ncbi.nlm.nih.gov/40163699/

  17. Kiyota N, Mizusawa J, Zenda S, Yokota T, Fujimoto Y, Wasano K, Kodaira T. Caution Needed Before Adopting Reduced-Dose Elective Neck Irradiation in Head and Neck Cancer: A Response to UPGRADE-RT.J Clin Oncol. 2025 Sep 10;43(26):2952-2953. doi: 10.1200/JCO-25-00928. Epub 2025 Jul 22.


    https://pubmed.ncbi.nlm.nih.gov/40694723/

  18. Sugitani I, Kiyota N, Ito Y, Onoda N, Hiromasa T, Horiuchi K, Kinuya S, Kondo T, Moritani S, Sugino K, Hara H. The 2024 revised clinical guidelines on the management of thyroid tumors by the Japan Association of Endocrine Surgery.Endocr J. 2025 May 7;72(5):545-635. doi: 10.1507/endocrj.EJ24-0644. Epub 2025 Mar 8.


    https://pubmed.ncbi.nlm.nih.gov/40058844/

  19. Watanabe T, Oka H, Nagashima K, Nishi H, Kumai Y, Iijima H, Okami K, Shimizu Y, Kano S, Ito K, Yamazaki T, Takahashi H, Oridate N, Yokota T, Koyama T, Kiyota N, Sato Y, Takahashi S, Kato K, Kadowaki S, Honma Y. Clinical outcomes of recurrent or metastatic head and neck cancer after failure of platinum and nivolumab: a multicenter retrospective study.Oncologist. 2025 Mar 10;30(3):oyaf018. doi: 10.1093/oncolo/oyaf018.


    https://pubmed.ncbi.nlm.nih.gov/40163686/

  20. Büttner M, Sykiotis G, Al-Ibraheem A, Pinto M, Iakovou I, Østhus AA, Hammerlid E, Locati LD, Gamper EM, Arraras JI, Jordan SJ, Kiyota N, Engesser D, Taylor K, Canotilho R, Ioannidis G, Husson O, Gama RR, Fanetti G, Moss L, Inhestern J, Andry G, Rimmele H, Singer S. Quality of life in thyroid cancer survivors with and without permanent hypoparathyroidism.Hormones (Athens). 2025 Sep;24(3):851-860. doi: 10.1007/s42000-025-00654-2. Epub 2025 Apr 23.


    https://pubmed.ncbi.nlm.nih.gov/40266537/

  21. Kano S, Kiyota N, Kinoshita I, Tada Y, Ijichi K, Yamazaki T, Shimizu Y, Hatanaka Y, Tsuda H, Morinaga S, Matsuno Y, Ito YM, Nishimoto N, Kobayashi K, Isoe T, Noguchi T, Homma A, Dosaka-Akita H. Multicenter phase II trial of trastuzumab and docetaxel for HER2-positive salivary gland cancer.Jpn J Clin Oncol. 2025 Oct 7;55(10):1131-1140. doi: 10.1093/jjco/hyaf106.


    https://pubmed.ncbi.nlm.nih.gov/40561362/

  22. Tang LL, Huang CL, Lin SJ, Le QT, O'Sullivan B, Yom SS, Huang SH, Chan AW, Lee N, Pan JJ, Mejia MBA, Ahn YC, Wong KCW, McDowell L, Orlandi E, Friborg J, Chen YP, Yasuda K, Kodaira T, Whitley AC, King AD, Prajogi GB, Hahn E, Lin JC, Kiyota N, Lee V, Ji PJ, Hitchcock Y, Hoebers F, Blanchard P, Moon SH, Wan Ishak WZ, Harrington KJ, Yang KY, Colevas AD, Lee A, Hu CS, Rosenthal D, Siddiqui F, Langendijk JA, Lang JY, Yi JL, Shen LF, Li JB, Liu LZ, Lee AWM, Mai HQ, Yang MK, Sun Y, Chua MLK, Ma J. Primary target volume delineation for radiotherapy in nasopharyngeal carcinoma: CSTRO, CACA, CSCO, HNCIG, ESTRO, and ASTRO guidelines and contouring atlas.Lancet Oncol. 2025 Sep;26(9):e477-e487.


    https://pubmed.ncbi.nlm.nih.gov/40907526/

  23. Tang LL, Huang CL, Lin SJ, Le QT, O'Sullivan B, Yom SS, Huang SH, Chan AW, Lee N, Pan JJ, Mejia MBA, Ahn YC, Wong KCW, McDowell L, Orlandi E, Friborg J, Chen YP, Yasuda K, Kodaira T, Whitley AC, King AD, Prajogi GB, Hahn E, Lin JC, Kiyota N, Lee V, Ji PJ, Hitchcock Y, Hoebers F, Blanchard P, Moon SH, Wan Ishak WZ, Harrington KJ, Yang KY, Colevas AD, Lee A, Hu CS, Rosenthal D, Siddiqui F, Langendijk JA, Lang JY, Yi JL, Shen LF, Li JB, Liu LZ, Lee AWM, Mai HQ, Yang MK, Sun Y, Chua MLK, Ma J. Target volume delineation of the neck for radiotherapy in nasopharyngeal carcinoma: CSTRO, CACA, CSCO, HNCIG, ESTRO, and ASTRO guidelines and contouring atlas.Lancet Oncol. 2025 Sep;26(9):e488-e498.


    https://pubmed.ncbi.nlm.nih.gov/40907527/

  24. Taylor KJ, Amdal CD, Bjordal K, Astrup GL, Herlofson BB, Duprez F, Gama RR, Jacinto A, Hammerlid E, Scricciolo M, Jansen F, Verdonck-de Leeuw IM, Fanetti G, Guntinas-Lichius O, Inhestern J, Dragan T, Fabian A, Boehm A, Wöhner U, Kiyota N, Krüger M, Bonomo P, Pinto M, Nuyts S, Silva JC, Stromberger C, Specenier P, Tramacere F, Bushnak A, Perotti P, Plath M, Paderno A, Stempler N, Kouri M, Grégoire V, Tribius S, Singer S;EORTC Quality of Life Group and the EORTC Head and Neck Group. Toxicities in long-term survivors of head and neck cancer-A multi-national cross-sectional analysis.Int J Cancer. 2025 Nov 15;157(10):2061-2070. doi: 10.1002/ijc.70033. Epub 2025 Jul 30.


    https://pubmed.ncbi.nlm.nih.gov/40735927/

  25. Bossi P, Kiyota N, Mesía R, Rosenberg AJ, Martino R, Fazer-Posorske C, Salmio S, Schroeder A, Yom SS. Adverse event profiles and management of cisplatin-based chemoradiotherapy in locally advanced head and neck squamous cell carcinoma: a systematic review.Oral Oncol. 2025 Oct:169:107596. doi: 10.1016/j.oraloncology.2025.107596. Epub 2025 Aug 25.


    https://pubmed.ncbi.nlm.nih.gov/40857970/

  26. Jansen F, Eerenstein SE, Taylor KJ, Amdal CD, Bjordal K, Astrup GL, Herlofson BB, Duprez F, Gama RR, Jacinto AA, Hammerlid E, Scricciolo M, Fanetti G, Guntinas-Lichius O, Inhestern J, Dragan T, Fabian A, Boehm A, Wöhner U, Kiyota N, Krüger M, Bonomo P, Pinto M, Nuyts S, Silva JC, Stromberger C, Specenier P, Tramacere F, Bushnak A, Perotti P, Plath M, Paderno A, Stempler N, Kanellopoulou A, Singer S, Verdonck-de Leeuw IM. Unmet supportive care needs among head and neck cancer survivors beyond 5 years after diagnosis: a multinational cohort study.Lancet Reg Health Eur. 2025 Oct 16:59:101495. doi: 10.1016/j.lanepe.2025.101495. eCollection 2025 Dec.


    https://pubmed.ncbi.nlm.nih.gov/41142659/

  27. Tang LL, Huang CL, Lin SJ, Le QT, O'Sullivan B, Yom SS, Huang SH, Chan AW, Lee N, Pan JJ, Mejia MBA, Ahn YC, Wong KCW, McDowell L, Orlandi E, Friborg J, Chen YP, Yasuda K, Kodaira T, Whitley AC, King AD, Prajogi GB, Hahn E, Lin JC, Kiyota N, Lee V, Ji PJ, Hitchcock Y, Hoebers F, Blanchard P, Moon SH, Wan Ishak WZ, Harrington KJ, Yang KY, Colevas AD, Lee A, Hu CS, Rosenthal D, Siddiqui F, Langendijk JA, Lang JY, Yi JL, Shen LF, Li JB, Liu LZ, Lee AWM, Mai HQ, Yang MK, Sun Y, Chua MLK, Ma J. Primary target volume delineation for radiotherapy in nasopharyngeal carcinoma: CSTRO, CACA, CSCO, HNCIG, ESTRO, and ASTRO guidelines and contouring atlas.Lancet Oncol. 2025 Sep;26(9):e477-e487. doi: 10.1016/S1470-2045(25)00326-2.


    https://pubmed.ncbi.nlm.nih.gov/40907526/

  28. Yamamoto K, Kurata K, Yakushijin K, Minami H. Ring Chromosomes 7 in Two Cases of Myelodysplastic Syndrome: Isolated Abnormality and Complex Karyotype Including idic(21)(p11.2) Duplication.Int J Lab Hematol. 2025 Oct;47(5):791-793. doi: 10.1111/ijlh.14499. Epub 2025 May 19.


    https://pubmed.ncbi.nlm.nih.gov/40387243/

  29. Yamazaki R, Yakushijin K, Yoshihara S, Ikeda K, Ishida A, Kajiwara M, Kikuta A, Takagi N, Nagamura-Inoue T, Namba N, Haraguchi K, Fujimori Y, Fujiwara SI, Yamada-Fujiwara M, Okuyama Y, Tanosaki R, Ueda Y. Evaluation of peripheral blood stem cell collection in the Japan Marrow Donor Program (JMDP).Transfusion. 2025 Dec;65(12):2345-2353. doi: 10.1111/trf.18458. Epub 2025 Nov 1.


    https://pubmed.ncbi.nlm.nih.gov/41175001/

  30. Masuko N, Tanimura K, Moriuchi K, Kita T, Obata K, Suda S, Imafuku H, Deguchi M, Kurata K, Yakushijin K, Kono K, Kawakatsu T, Terai Y. Plateletpheresis for treating essential thrombocythemia that developed during pregnancy: A case report.Taiwan J Obstet Gynecol. 2025 Jul;64(4):703-706. doi: 10.1016/j.tjog.2025.01.008.


    https://pubmed.ncbi.nlm.nih.gov/40602969/

  31. Yoshimura K, Nakasone H, Tamaki M, Hosoi H, Kameda K, Uchida N, Doki N, Fukuda T, Yoshihara S, Mori Y, Nakamae H, Tanaka M, Katayama Y, Eto T, Hasegawa Y, Ota S, Takahashi S, Yoshimitsu M, Ishimaru F, Kanda J, Atsuta Y, Yakushijin K. Impact of Conditioning Intensity on Clinical Outcomes of Second Allogeneic Hematopoietic Cell Transplantation for Relapse After First Transplantation.Am J Hematol. 2025 Jul;100(7):1185-1195. doi: 10.1002/ajh.27709. Epub 2025 May 23.


    https://pubmed.ncbi.nlm.nih.gov/40407015/

  32. Masuda K, Kataoka K, Sakurai M, Najima Y, Harada N, Ukita S, Uchida N, Doki N, Fukuda T, Tanaka M, Ohigashi H, Ishikawa J, Yoshihara S, Sawa M, Ota S, Kanda Y, Nishida T, Onizuka M, Atsuta Y, Nakasone H, Yakushijin K. Classical and Late-Onset SOS/VOD After Allogeneic HSCT: A Japanese Transplant Registry Analysis.Am J Hematol. 2025 Aug;100(8):1283-1294. doi: 10.1002/ajh.27715. Epub 2025 May 19.


    https://pubmed.ncbi.nlm.nih.gov/40387331/

  33. Akahoshi Y, Nakasone H, Takenaka K, Ara T, Tada Y, Doki N, Uchida N, Tanaka M, Hasegawa Y, Takeda W, Nishida T, Ishikawa J, Kurita N, Sawa M, Onizuka M, Kako S, Fujiwara SI, Kataoka K, Kawamura K, Fukuda T, Atsuta Y, Yakushijin K, Kanda Y. Heterogeneity of Survival Benefit Conferred By Letermovir.Transplant Cell Ther. 2025 Jul;31(7):461.e1-461.e12. doi: 10.1016/j.jtct.2025.04.010. Epub 2025 Apr 28.


    https://pubmed.ncbi.nlm.nih.gov/40306552/

  34. Kato M, Nakashone H, Matsuo K, Ito Y, Yanagisawa A, Ohbiki M, Tabuchi K, Ichinohe T, Hashii Y, Kanda J, Goto H, Kato K, Yoshimitsu M, Sato A, Hino M, Matsumoto K, Yakushijin K, Atsuta Y, Fukuda T. Impact of center volume on outcomes in allogeneic hematopoietic cell transplantation for children.Bone Marrow Transplant. 2025 Jun;60(6):851-856. doi: 10.1038/s41409-025-02569-3. Epub 2025 Apr 10.


    https://pubmed.ncbi.nlm.nih.gov/40211066/

  35. Misaki Y, Tamaki M, Yanagisawa R, Doki N, Uchida N, Tanaka M, Nishida T, Sawa M, Hasegawa Y, Ota S, Onizuka M, Mamiko SY, Katayama Y, Asada N, Kanda J, Fukuda T, Atsuta Y, Kanda Y, Yakushijin K, Nakasone H. Adverse Impact of Pre-Transplant Liver Dysfunction in Allogeneic Hematopoietic Cell Transplantation.Am J Hematol. 2025 May;100(5):821-829. doi: 10.1002/ajh.27652. Epub 2025 Mar 8.


    https://pubmed.ncbi.nlm.nih.gov/40056058/

  36. Fujimoto A, Miyazaki K, Yakushijin K, Fujino T, Munakata W, Ejima Y, Maruyama D, Kubota N, Maeda T, Takizawa J, Hiramoto N, Takeuchi M, Sakai R, Fukuhara N, Taguchi S, Asano N, Yamaguchi M, Suzuki R. Improved prognosis of advanced-stage extranodal NK/T-cell lymphoma: results of the NKEA-Next study.Leukemia. 2025 Apr;39(4):909-916. doi: 10.1038/s41375-025-02527-4. Epub 2025 Feb 17.


    https://pubmed.ncbi.nlm.nih.gov/39962328/

  37. Phi LTH, Cheng Y, Funakoshi Y, Bertucci F, Finetti P, Van Laere SJ, Zou F, Long JP, Ogata S, Krishnamurthy S, Reuben JM, Foulks JM, Warner SL, Rosenbluth JM, Sood AK, Tripathy D, Ueno NT, Wang X. AXL promotes inflammatory breast cancer progression by regulating immunosuppressive macrophage polarization.Breast Cancer Res. 2025 May 6;27(1):70. doi: 10.1186/s13058-025-02015-8.


    https://pubmed.ncbi.nlm.nih.gov/40329335/

  38. Fujimoto A, Miyazaki K, Yakushijin K, Fujino T, Munakata W, Ejima Y, Maruyama D, Kubota N, Maeda T, Takizawa J, Hiramoto N, Takeuchi M, Sakai R, Fukuhara N, Taguchi S, Asano N, Yamaguchi M, Suzuki R. Improved prognosis of advanced-stage extranodal NK/T-cell lymphoma: results of the NKEA-Next study.Leukemia. 2025 Apr;39(4):909-916. doi: 10.1038/s41375-025-02527-4. Epub 2025 Feb 17.


    https://pubmed.ncbi.nlm.nih.gov/39962328/

  39. Tamaki M, Kawamura S, Takano K, Nakamae H, Doki N, Ohigashi H, Maruyama Y, Ota S, Hiramoto N, Eto T, Yoshihara S, Matsuoka KI, Masuko M, Onizuka M, Kanda Y, Fukuda T, Atsuta Y, Yanagisawa R, Yakushijin K, Nakasone H. Female-to-male allogeneic transplantation affects outcomes differently according to the type of haplo-transplantation.Cytotherapy. 2025 Feb;27(2):213-221. doi: 10.1016/j.jcyt.2024.09.007. Epub 2024 Oct 5.


    https://pubmed.ncbi.nlm.nih.gov/39453336/